Shilpa Medicare marketing partner unveils Pemrydi Rtu in US
PEMRYDI RTU is a novel ready-to-use injection which eliminates the need for refrigeration or reconstitution and dilution for administration to the patient.
Karnataka: Shilpa Medicare's marketing partner, Amneal Pharmaceuticals, has launched PEMRYDI RTU (Pemetrexed injection 10 mg/mL), the first ready-to-use pemetrexed formulation in the US market.
The product has already been granted permanent J-code (J9324) by U.S. Centers for Medicare & Medicaid Services (CMS).
Read also: Shilpa Medicare gets Code J for Pemetrexed Injection
Pemetrexed Injection is used as a drug, in the treatment of non-small cell lung cancer in combination with other chemotherapy agents. It is also indicated in the treatment of mesothelioma in combination with cisplatin.
PEMRYDI RTU is a novel ready-to-use injection which eliminates the need for refrigeration or reconstitution and dilution for administration to the patient. This offers hospitals and oncology clinics a new, value-added presentation that should improve pharmacy efficiency by eliminating preparation steps and freeing up refrigerator space.
Currently product is available in two vial sizes: 100mg/10mL and 500 mg/50mL, and we intend to introduce 1000mg/100mL soon in the market.
According to IQVIA, U.S. annual sales for pemetrexed for the 12 months ended February 2024 were $287 million.
Shilpa Medicare Limited, headquartered at Raichur, Karnataka, India, is a vertically integrated, manufacturer and distributor of quality drugs to global markets; specializing in the Oncology therapeutic segment and introducing novel drugs focusing on patient convenience and compliance.
Read also: USFDA closes inspection at Shilpa Medicare Hyderabad lab
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.